Modulation of Nrf2 by olive oil and wine polyphenols and neuroprotection

Antioxidants

Volumn 6, Issue 4, 2017, Pages

  Martínez Huélamo, Miriam ^a   Rodríguez Morató, Jose ^a,b,c   Boronat, Anna ^a,b   de la Torre, Rafael ^a,b,c  

^a HOSPITAL DEL MAR   (Spain)

^b UNIVERSITAT POMPEU FABRA   (Spain)

^c Instituto de Salud Carlos III   (Spain)

Author keywords

Cognitive function; Hydroxytyrosol; Nrf2; Olive oil; Polyphenols; Resveratrol; Wine

Indexed keywords

EID: 85045438694     PISSN: None     EISSN: 20763921     Source Type: Journal    
DOI: 10.3390/antiox6040073     Document Type: Review

References (158)

1. Estruch, R.; Salas-Salvadó, J. Towards an even healthier mediterranean diet. Nutr. Metab. Cardiovasc. Dis. 2013, 23, 1163–1166. [CrossRef] [PubMed]
2. Estruch, R.; Ros, E.; Salas-Salvadó, J.; Covas, M.-I.; Corella, D.; Arós, F.; Gómez-Gracia, E.; Ruiz-Gutiérrez, V.; Fiol, M.; Lapetra, J., et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet. N. Engl. J. Med. 2013, 368, 1279–1290. [CrossRef] [PubMed]
3. Loughrey, D.G.; Lavecchia, S.; Brennan, S.; Lawlor, B.A.; Kelly, M.E. The impact of the Mediterranean diet on the cognitive functioning of healthy older adults: A systematic review and meta-analysis. Adv. Nutr. Int. Rev. J. 2017, 8, 571–586.
4. Liyanage, T.; Ninomiya, T.; Wang, A.; Neal, B.; Jun, M.; Wong, M.G.; Jardine, M.; Hillis, G.S.; Perkovic, V. Effects of the Mediterranean diet on cardiovascular outcomes-a systematic review and meta-analysis. PLoS ONE 2016, 11, e0159252. [CrossRef] [PubMed]
5. Valls-Pedret, C.; Lamuela-Raventós, R.M.; Medina-Remón, A.; Quintana, M.; Corella, D.; Pintó, X.; Martínez-González, M.Á.; Estruch, R.; Ros, E. Polyphenol-rich foods in the Mediterranean diet are associated with better cognitive function in elderly subjects at high cardiovascular risk. J. Alzheimers Dis. 2012, 29, 773–782. [PubMed]
6. Scalbert, A.; Manach, C.; Morand, C.; Rémésy, C.; Jiménez, L. Dietary polyphenols and the prevention of diseases. Crit. Rev. Food Sci. Nutr. 2005, 45, 287–306. [CrossRef] [PubMed]
7. Parkinson, L.; Cicerale, S. The health benefiting mechanisms of virgin olive. Molecules 2016, 21, 1734. [CrossRef] [PubMed]
8. Martín-Peláez, S.; Covas, M.I.; Fitó, M.; Kusar, A.; Pravst, I. Health effects of olive oil polyphenols: Recent advances. Mol. Nutr. Food Res. 2013, 57, 760–771. [CrossRef] [PubMed]
9. Covas, M.-I.; Nyyssönen, K.K.; Poulsen, H.E.; Kaikkonen, J.; Zunft, H.F.; Kiesewetter, H.; Gaddi, A.; De La Torre, R.; Mursu, J.; Bäumler, H., et al. The effect of polyphenols in olive oil on heart disease risk factors. Ann. Intern. Med. 2006, 145, 333–341. [CrossRef] [PubMed]
10. EFSA Panel on Dietetic Products, Nutrition and allergies (NDA). Scientific opinion on the substantiation of health claims related to polyphenols in olive and protection of LDL particles from oxidative damage. Eur. Food Saf. Authority J. 2011. [CrossRef]
11. Granados-Principal, S.; Quiles, J.L.; Ramirez-tortosa, C.L.; Sanchez-Rovira, P.; Ramirez-Tortosa, M.C. Hydroxytyrosol: From laboratory investigations to future clinical trials. Nutr. Rev. 2010, 68, 191–206. [CrossRef] [PubMed]
12. Covas, M.I.; De La Torre, R.; Fitó, M. Virgin olive oil: A key food for cardiovascular risk protection. Br. J. Nutr. 2015, 133, S19–S28. [CrossRef] [PubMed]
13. Servili, M.; Montedoro, G. Contribution of phenolic compounds to virgin olive oil quality. Eur. J. Lipid Sci. Technol. 2002, 104, 602–613. [CrossRef]
14. Rodríguez-Morató, J.; Xicota, L.; Fitó, M.; Farré, M.; Dierssen, M.; De la Torre, R. Potential Role of Olive Oil Phenolic Compounds in the Prevention of Neurodegenerative Diseases. Molecules 2015, 20, 4655–4680. [CrossRef] [PubMed]
15. Sánchez-Quesada, C.; López-Biedma, A.; Warleta, F.; Campos, M.; Beltrán, G.; Gaforio, J.J. Bioactive properties of the main triterpenes found in olives, virgin olive oil, and leaves of Olea europaea. J. Agric. Food Chem. 2013, 61, 12173–12182. [CrossRef] [PubMed]
16. Servili, M.; Sordini, B.; Esposto, S.; Urbani, S.; Veneziani, G.; Maio, I.D.; Selvaggini, R.; Taticchi, A. Biological activities of phenolic compounds of extra virgin olive oil. Antioxidants 2014, 3, 1–23. [CrossRef] [PubMed]
17. Visioli, F.; Poli, A.; Galli, C. Antioxidant and other biological activities of phenols from olives and olive oil. Med. Res. Rev. 2002, 22, 65–75. [CrossRef] [PubMed]
18. Karkoula, E.; Skantzari, A.; Melliou, E.; Magiatis, P. Quantitative measurement of major secoiridoid derivatives in olive. J. Agric. Food Chem. 2014, 62, 600–607. [CrossRef] [PubMed]
19. Rodríguez-Morató, J.; Boronat, A.; Kotronoulas, A.; Pujadas, M.; Pastor, A.; Olesti, E.; Pérez-Mañá, C.; Khymenets, O.; Fitó, M.; Farré, M., et al. Metabolic disposition and biological significance of simple phenols of dietary origin: Hydroxytyrosol and tyrosol. Drug Metab. Rev. 2016, 48, 218–236. [CrossRef] [PubMed]
20. Stockley, C.; Teissedre, P.; Boban, M.; Di Lorenzo, C.; Restani, P. Bioavailability of wine-derived phenolic compounds in humans: A review. Food Funct. 2012, 3, 995–1007. [CrossRef] [PubMed]
21. German, J.B.; Walzem, R.L. The health benefits of wine. Annu. Rev. Nutr. 2000, 20, 561–593. [CrossRef] [PubMed]
22. Basli, A.; Soulet, S.; Chaher, N.; Mérillon, J.-M.; Chibane, M.; Monti, J.-P.; Richard, T. Wine polyphenols: Potential agents in neuroprotection. Oxid. Med. Cell. Longev. 2012. [CrossRef] [PubMed]
23. Waterhouse, A.L.Wine phenolics. Ann. N. Y. Acad. Sci. 2002, 957, 21–36. [CrossRef] [PubMed]
24. Caruana, M.; Cauchi, R.; Vassallo, N. Putative role of red wine polyphenols against brain pathology in Alzheimer’s and Parkinson’s Disease. Front Nutr. 2016, 3, 31. [CrossRef] [PubMed]
25. Ferruzzi, M.G.; Lobo, J.K.; Janle, E.M.; Whittaker, N.; Cooper, B.; Simon, J.E.; Wu, Q.L.; Welch, C.; Ho, L.; Weaver, C., et al. Bioavailability of gallic and catechins from grape seed polyphenol extract is improved by repeated dosing in rats: Implications for treatment in Alzheimer’s Disease. J. Alzheimers Dis. 2010, 18, 113–124. [CrossRef] [PubMed]
26. Lovera, J.; Ramos, A.; Devier, D.; Garrison, V.; Kovner, B.; Reza, T.; Koop, D.; Rooney, W.; Foundas, A.; Bourdette, D. Polyphenon E, non-futile at neuroprotection in multiple sclerosis but unpredictably hepatotoxic: Phase I single group and phase II randomized placebo-controlled studies. J. Neurol. Sci. 2016, 358, 46–52. [CrossRef] [PubMed]
27. Terao, J. Factors modulating bioavailability of quercetin-related flavonoids and the consequences of their vascular function. Biochem. Pharmacol. 2017, 139, 15–23. [CrossRef] [PubMed]
28. Islam, M.A.; Bekele, R.; Vanden Berg, J.H.J.; Kuswanti, Y.; Thapa, O.; Soltani, S.; Van Leeuwen, F.X.; Rietjens, I.M.; Murk, A.J. Deconjugation of soy isoflavone glucuronides needed for estrogenic activity. Toxicol. Vitr. 2015, 29, 706–715. [CrossRef] [PubMed]
29. Faria, A.; Meireles, M.; Fernandes, I.; Santos-Buelga, C.; Gonzalez-Manzano, S.; Dueñas, M.; De Freitas, V.; Mateus, N.; Calhau, C. Flavonoid metabolites transport across a human BBB model. Food Chem. 2014, 149, 190–196. [CrossRef] [PubMed]
30. Serra, A.; Rubió, L.; Borràs, X.; Macià, A.; Romero, M.P.; Motilva, M.J. Distribution of olive oil phenolic compounds in rat tissues after administration of a phenolic extract from olive cake. Mol. Nutr. Food Res. 2012, 56, 486–496. [CrossRef] [PubMed]
31. Konstantinidou, V.; Covas, M.I.; Sola, R.; Fitó, M. Up-to date knowledge on the in vivo transcriptomic effect of the Mediterranean diet in humans. Mol. Nutr. Food Res. 2013, 57, 772–783. [CrossRef] [PubMed]
32. Konstantinidou, V.; Covas, M.-I.; Muñoz-Aguayo, D.; Khymenets, O.; De la Torre, R.; Saez, G.; Tormos Mdel, C.; Toledo, E.; Marti, A.; Ruiz-Gutiérrez, V., et al. In vivo nutrigenomic effects of virgin olive oil polyphenols within the frame of the Mediterranean diet: A randomized controlled trial. FASEB J. 2010, 24, 2546–2557. [CrossRef] [PubMed]
33. Spencer, J.P.E. The interactions of flavonoids within neuronal signalling pathways. Genes Nutr. 2007, 2, 257–273. [CrossRef] [PubMed]
34. Williams, R.J.; Spencer, J.P.E.; Rice-Evans, C. Flavonoids and isoflavones (phytoestrogens): Absorption, metabolism, and bioactivity. Free Radic. Biol. Med. 2004, 36, 838–849. [CrossRef] [PubMed]
35. Ramassamy, C. Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: A review of their intracellular targets. Eur. J. Pharmacol. 2006, 545, 51–64. [CrossRef] [PubMed]
36. Wang, J.; Ho, L.; Zhao, Z.; Seror, I.; Humala, N.; Dickstein, D.L.; Thiyagarajan, M.; Percival, S.S.; Talcott, S.T.; Pasinetti, G.M. Moderate consumption of Cabernet Sauvignon attenuates Aβ neuropathology in a mouse model of Alzheimer’s disease. FASEB J. 2006, 20, 2313–2320. [CrossRef] [PubMed]
37. Pasinetti, G.M. Novel role of red wine-derived polyphenols in the prevention of Alzheimer’s disease dementia and brain pathology: Experimental approaches and clinical implications. Planta Med. 2012, 78, 1614–1619. [PubMed]
38. Diebolt, M.; Bucher, B.; Andriantsitohaina, R. Wine polyphenols decrease blood pressure, improve NO vasodilatation, and induce gene expression. Hypertension 2001, 38, 159–165. [CrossRef] [PubMed]
39. Milenkovic, D.; Jude, B.; Morand, C. miRNA as molecular target of polyphenols underlying their biological effects. Free Radic. Biol. Med. 2013, 64, 40–51. [CrossRef] [PubMed]
40. Corona, G.; Vauzour, D.; Hercelin, J.; Williams, C.M.; Spencer, J.P.E. Phenolic acid intake, delivered via moderate champagne wine consumption, improves spatial working memory via the modulation of hippocampal and cortical protein expression/activation. Antioxid. Redox Signal. 2013, 19, 1676–1689. [CrossRef] [PubMed]
41. Scapagnini, G.; Sonya, V.; Abraham, N.G.; Calogero, C.; Zella, D.; Fabio, G. Modulation of Nrf2/ARE pathway by food polyphenols: A nutritional neuroprotective strategy for cognitive and neurodegenerative disorders. Mol. Neurobiol. 2011, 44, 192–201. [CrossRef] [PubMed]
42. Tramutola, A.; Lanzillotta, C.; Perluigi, M.; Butterfield, D.A. Oxidative stress, protein modification and Alzheimer disease. Brain Res. Bull. 2017, 133, 88–96. [CrossRef] [PubMed]
43. Padurariu, M.; Ciobica, A.; Lefter, R.; Serban, I.L. The oxidative stress hypothesis in Alzheimer’s disease. Psychiatr. Danub. 2013, 25, 401–409. [PubMed]
44. Peng, C.; Wang, X.; Chen, J.; Jiao, R.; Wang, L.; Li, Y.M.; Zuo, Y.Y.; Liu, Y.W.; Lei, L.; Ma, K.Y., et al. Biology of ageing and role of dietary antioxidants. Biomed. Res. Int. 2014, 2014, 831841. [CrossRef] [PubMed]
45. Valko, M.; Leibfritz, D.; Moncol, J.; Cronin, M.T.D.; Mazur, M.; Telser, J. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol. 2007, 39, 44–84. [CrossRef] [PubMed]
46. Videla, L.A.; Fernández, V.; Cornejo, P.; Vargas, R. Metabolic basis for thyroid hormone liver preconditioning: Upregulation of AMP-activated protein kinase signaling. Sci. World J. 2012, 2012, 475675. [CrossRef] [PubMed]
47. Jin, H.; Kanthasamy, A.; Ghosh, A.; Anantharam, V.; Kalyanaraman, B.; Kanthasamy, A.G.Mitochondria-targeted antioxidants for treatment of Parkinson’s disease: Preclinical and clinical outcomes. Biochim. Biophys. Acta 2014, 1842, 1282–1294. [CrossRef] [PubMed]
48. Sheu, S.-S.; Nauduri, D.; Anders, M.W. Targeting antioxidants to mitochondria: A new therapeutic direction. Biochim. Biophys. Acta 2006, 1762, 256–265. [CrossRef] [PubMed]
49. Balaban, R.S.; Nemoto, S.; Finkel, T. Mitochondria, oxidants, and aging. Cell 2005, 120, 483–495. [CrossRef] [PubMed]
50. Kizhakekuttu, T.J.; Widlansky, M.E. Natural antioxidants and hypertension: Promise and challenges. Cardiovasc. Ther. 2010, 28, 20–32. [CrossRef] [PubMed]
51. Ojala, J.O.; Sutinen, E.M. The role of interleukin-18, oxidative stress and metabolic syndrome in Alzheimer’s disease. J. Clin. Med. 2017, 6, 55. [CrossRef] [PubMed]
52. Deshmukh, P.; Unni, S.; Krishnappa, G.; Padmanabhan, B. The Keap1-Nrf2 pathway: Promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases. Biophys. Rev. 2017, 9, 41–56. [CrossRef] [PubMed]
53. Paloczi, J.; Varga, Z.V.; Hasko, G.; Pacher, P. Neuroprotection in oxidative stress-related neurodegenerative diseases: Role of endocannabinoid system modulation. Antioxid. Redox Signal. 2017. [CrossRef] [PubMed]
54. Manoharan, S.; Guillemin, G.J.; Abiramasundari, R.S.; Essa, M.M.; Akbar, M.; Akbar, M.D. The role of reactive oxygen species in the pathogenesis of Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease: A mini review. Oxid. Med. Cell. Longev. 2016, 2016, 8590578. [CrossRef] [PubMed]
55. Bhat, A.H.; Dar, K.B.; Anees, S.; Zargar, M.A.; Masood, A.; Sofi, M.A.; Ganie, S.A. Oxidative stress, mitochondrial dysfunction and neurodegenerative diseases; A mechanistic insight. Biomed. Pharmacother. 2015, 74, 101–110. [CrossRef] [PubMed]
56. Ortiz, G.G.; Pacheco Moisés, F.P.; Mireles-Ramírez, M.; Flores-Alvarado, L.J.; González-Usigli, H.; Sánchez-González, V.J.; Sánchez-López, A.L.; Sánchez-Romero, L.; Díaz-Barba, E.I.; Santoscoy-Gutiérrez, J.F., et al. Oxidative stress: Love and hate history in central nervous system. Adv. Protein Chem. Struct. Biol. 2017. [CrossRef]
57. Ratnam, D.V.; Ankola, D.D.; Bhardwaj, V.; Sahana, D.K.; Kumar, M.N.V.R. Role of antioxidants in prophylaxis and therapy: A pharmaceutical perspective. J. Control. Release 2006, 113, 189–207. [CrossRef] [PubMed]
58. Bagli, E.; Goussia, A.; Moschos, M.M.; Agnantis, N.; Kitsos, G. Natural compounds and neuroprotection: Mechanisms. In Vivo (Brooklyn) 2016, 30, 535–548.
59. Jing, X.; Wei, X.; Ren, M.; Wang, L.; Zhang, X.; Lou, H. Neuroprotective effects of Tanshinone I against 6-OHDA-induced oxidative stress in cellular and mouse model of Parkinson’s disease through upregulating Nrf2. Neurochem. Res. 2016, 41, 779–786. [CrossRef] [PubMed]
60. Zhao, F.; Wu, T.; Lau, A.; Jiang, T.; Huang, Z.; Wang, X.J.; Chen, W.M.; Wong, P.K.; Zhang, D.D. Nrf2 promotes neuronal cell differentiation. Free Radic. Biol. Med. 2009, 47, 867–879. [CrossRef] [PubMed]
61. Calkins, M.J.; Johnson, D.A.; Townsend, J.A.; Vargas, M.R.; Dowell, J.A.; Williamson, T.P.; Kraft, A.D.; Lee, J.-M.; Li, J.; Johnson, J.A. The Nrf2/ARE pathway as a potential therapeutic target in neurodegenerative disease. Antioxid. Redox Signal. 2009, 11, 497–508. [CrossRef] [PubMed]
62. Belcher, J.D.; Chen, C.; Nguyen, J.; Zhang, P.; Abdulla, F.; Nguyen, P.; Killeen, T.; Xu, P.; O’Sullivan, G.; Nath, K.A., et al. Control of oxidative stress and inflammation in sickle cell disease with the Nrf2 activator dimethyl fumarate. Antioxid. Redox Signal. 2017, 26, 748–762. [CrossRef] [PubMed]
63. Lastres-Becker, I.; García-Yagüe, A.J.; Scannevin, R.H.; Casarejos, M.J.; Kügler, S.; Rábano, A.; Cuadrado, A. Repurposing the NRF2 activator dimethyl fumarate as therapy against synucleinopathy in Parkinson’s disesase. Antioxid. Redox Signal 2016, 25, 61–77. [CrossRef] [PubMed]
64. Mutter, F.E.; Park, B.K.; Copple, I.M. Value of monitoring Nrf2 activity for the detection of chemical and oxidative stress. Biochem. Soc. Trans. 2015, 43, 657–662. [CrossRef] [PubMed]
65. González-Reyes, S.; Guzmán-Beltrán, S.; Medina-Campos, O.N.; Pedraza-Chaverri, J. Curcumin pretreatment induces Nrf2 and an antioxidant response and prevents hemin-induced toxicity in primary cultures of cerebellar granule neurons of rats. Oxid. Med. Cell. Longev. 2013, 2013, 801418. [CrossRef] [PubMed]
66. Kim, G.H.; Kim, J.E.; Rhie, S.J.; Yoon, S. The role of oxidative stress in neurodegenerative diseases. Exp. Neurobiol. 2015, 24, 325–340. [CrossRef] [PubMed]
67. Nguyen, T.; Sherratt, P.J.; Pickett, C.B. Regulatory mechanisms controlling gene expression mediated by the antioxidant response element. Annu. Rev. Pharmacol. Toxicol. 2003, 43, 233–260. [CrossRef] [PubMed]
68. Kong, A.-N.T.; Owuor, E.; Yu, R.; Hebbar, V.; Chen, C.; Hu, R.; Mandlekar, S. Induction of xenobiotic enzymes by the MAP kinase pathway and the antioxidant or electrophile response element (ARE/EpRE). Drug Metab. Rev. 2001, 33, 255–271. [CrossRef] [PubMed]
69. Itoh, K.; Tong, K.I.; Yamamoto, M. Molecular mechanism activating Nrf2-Keap1 pathway in regulation of adaptive response to electrophiles. Free Radic. Biol. Med. 2004, 36, 1208–1213. [CrossRef] [PubMed]
70. Liddell, J. Are astrocytes the predominant cell type for activation of Nrf2 in aging and neurodegeneration? Antioxidants 2017, 6, 65. [CrossRef] [PubMed]
71. Ganguly, G.; Chakrabarti, S.; Chatterjee, U.; Saso, L. Proteinopathy, oxidative stress and mitochondrial dysfunction: Cross talk in Alzheimer’s disease and Parkinson’s disease. Drug Des. Devel. Ther. 2017, 11, 797–810. [CrossRef] [PubMed]
72. Chen, Z.; Zhong, C. Oxidative stress in Alzheimer’s disease. Neurosci. Bull. 2014, 30, 271–281. [CrossRef] [PubMed]
73. Amin, F.U.; Shah, S.A.; Kim, M.O. Vanillic acid attenuates Aβ1-42-induced oxidative stress and cognitive impairment in mice. Sci. Rep. 2017, 7, 1–15. [CrossRef] [PubMed]
74. Zhou, J.; Chao, G.; Li, Y.; Wu, M.; Zhong, S.; Feng, Z. Activation of NRF2/ARE by isosilybin alleviates Aβ25-35-induced oxidative stress injury in HT-22 cells. Neurosci. Lett. 2016, 632, 92–97. [CrossRef] [PubMed]
75. Wang, Y.; Miao, Y.; Zia, A.; Cheng, L.; Wang, L.; Zhao, L.; Cui, Q.F.; Zhao, W.L.; Wang, H.Q. Inhibition of beta-amyloid-induced neurotoxicity by pinocembrin through Nrf2/HO-1 pathway in SH-SY5Y cells. J. Neurol. Sci. 2016, 368, 223–230. [CrossRef] [PubMed]
76. Wong, S.L.; Gilmour, H.; Ramage-Morin, P.L. Parkinson’s disease: Prevalence, diagnosis and impact. Health Rep. 2014, 25, 10–14. [PubMed]
77. Cacabelos, R. Parkinson’s disease: From pathogenesis to pharmacogenomics. Int. J. Mol. Sci. 2017, 18, 551. [CrossRef] [PubMed]
78. Blesa, J.; Trigo-Damas, I.; Quiroga-Varela, A.; Jackson-Lewis, V.R. Oxidative stress and Parkinson’s disease. Front. Neuroanat. 2015, 9, 1–9. [CrossRef] [PubMed]
79. Masaki, Y.; Izumi, Y.; Matsumura, A.; Akaike, A.; Kume, T. Protective effect of Nrf2-ARE activator isolated from green perilla leaves on dopaminergic neuronal loss in a Parkinson’s disease model. Eur. J. Pharmacol. 2017, 798, 26–34. [CrossRef] [PubMed]
80. Cui, Q.; Li, X.; Zhu, H. Curcumin ameliorates dopaminergic neuronal oxidative damage via activation of the Akt/Nrf2 pathway. Mol. Med. Rep. 2016, 13, 1381–1388. [CrossRef] [PubMed]
81. Huntington Disease. Available online: https://ghr.nlm.nih.gov/condition/huntington-disease#definition (accessed on 27 June 2015).
82. Machiela, E.; Dues, D.J.; Senchuk, M.M.; Van Raamsdonk, J.M. Oxidative stress is increased in C. elegans models of Huntington’s disease but does not contribute to polyglutamine toxicity phenotypes. Neurobiol. Dis. 2016, 96, 1–11. [CrossRef] [PubMed]
83. Pérez-severiano, F.; Montes, S.; Gerónimo-olvera, C.; Segovia, J. Study of oxidative damage and antioxidant systems in two Huntington’s disease rodent models. Metods Mol. Biol. 2013, 1010, 177–200.
84. Ciancarelli, I.; De Amicis, D.; Di Massimo, C.; Di Scanno, C.; Pistarini, C.; D’Orazio, N.; Ciancarelli, M.G.T. Peripheral biomarkers of oxidative stress and their limited potential in evaluation of clinical features of Huntington’s patients. Biomarkers 2014, 19, 452–456. [CrossRef] [PubMed]
85. Sandhir, R.; Yadav, A.; Mehrotra, A.; Sunkaria, A.; Singh, A.; Sharma, S. Curcumin nanoparticles attenuate neurochemical and neurobehavioral deficits in experimental model of Huntington’s disease. Neuromol. Med. 2013, 16, 106–118. [CrossRef] [PubMed]
86. Oliveira, A.M.; Cardoso, S.M.; Ribeiro, M.; Seixas, R.S.G.R.; Silva, A.M.S.; Rego, A.C. Protective effects of 3-alkyl luteolin derivatives are mediated by Nrf2 transcriptional activity and decreased oxidative stress in Huntington’s disease mouse striatal cells. Neurochem. Int. 2015, 91, 1–12. [CrossRef] [PubMed]
87. Gao, Y.; Chu, S.; Li, J.; Zhang, Z.; Yan, J.; Wen, Z.; Xia, C.-Y.; Mou, Z.; Wang, Z.-Z.; He, W.-B., et al. Protopanaxtriol protects against 3-nitropropionic acid-induced oxidative stress in a rat model of Huntington’s disease. Acta Pharmacol. Sin. 2015, 36, 311–322. [CrossRef] [PubMed]
88. Stack, C.; Ho, D.; Wille, E.; Calingasan, N.Y.; Williams, C.; Liby, K.; Sporn, M.; Dumont, M.; Flint Beal, M. Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington’s disease. Free Radic. Biol. Med. 2010, 49, 147–158. [CrossRef] [PubMed]
89. Ghaiad, H.R.; Nooh, M.M.; El-Sawalhi, M.M.; Shaheen, A.A. Resveratrol promotes remyelination in cuprizone model of multiple sclerosis: Biochemical and histological study. Mol. Neurobiol. 2016, 54, 3219–3229. [CrossRef] [PubMed]
90. Delgado-Roche, L.; Riera-Romo, M.; Mesta, F.; Hernández-Matos, Y.; Barrios, J.M.; Martínez-Sánchez, G.; Al-Dalaien, S.M. Medical ozone promotes Nrf2 phosphorylation reducing oxidative stress and pro-inflammatory cytokines in multiple sclerosis patients. Eur. J. Pharmacol. 2017, 811, 148–154. [CrossRef] [PubMed]
91. Ferreira, K.P.Z.; Oliveira, S.R.; Kallaur, A.P.; Kaimen-Maciel, D.R.; Lozovoy, M.A.B.; De Almeida, E.R.D.; Morimoto, H.K.; Mezzaroba, L.; Dichi, I.; Reiche, E.M.V., et al. Disease progression and oxidative stress are associated with higher serum ferritin levels in patients with multiple sclerosis. J. Neurol. Sci. 2017, 373, 236–241. [CrossRef] [PubMed]
92. Choi, I.-Y.; Lee, P.; Adany, P.; Hughes, A.J.; Belliston, S.; Denney, D.R.; Lynch, S.G. In vivo evidence of oxidative stress in brains of patients with progressive multiple sclerosis. Mult. Scler. J. 2017. [CrossRef] [PubMed]
93. Zhang, Q.; Li, Z.; Wu, S.; Li, X.; Sang, Y.; Li, J.; Niu, Y.H.; Ding, H. Myricetin alleviates cuprizone-induced behavioral dysfunction and demyelination in mice by Nrf2 pathway. Food Funct. 2016, 7, 4332–4342. [CrossRef] [PubMed]
94. Gopal, S.; Mikulskis, A.; Gold, R.; Fox, R.J.; Dawson, K.T.; Amaravadi, L. Evidence of activation of the Nrf2 pathway in multiple sclerosis patients treated with delayed-release dimethyl fumarate in the Phase 3 DEFINE and CONFIRM studies. Mult. Scler. J. 2017, 2, 1–9. [CrossRef] [PubMed]
95. Wang, Q.; Chuikov, S.; Taitano, S.; Wu, Q.; Rastogi, A.; Tuck, S.J.; Corey, J.M.; Lundy, S.K.; Mao-Draayer, Y. Dimethyl fumarate protects neural stem/progenitor cells and neurons from oxidative damage through Nrf2-ERK1/2 MAPK pathway. Int. J. Mol. Sci. 2015, 16, 13885–13907. [CrossRef] [PubMed]
96. Jiang, L.; Zhang, S.; Li, C.; Tang, J.; Che, F.; Lu, Y. Roles of the Nrf2/HO-1 pathway in the anti-oxidative stress response to ischemia-reperfusion brain injury in rats. Eur. Rev. Med. Pharmacol. Sci. 2017, 21, 1532–1540. [PubMed]
97. Cai, M.; Guo, Y.; Wang, S.; Wei, H.; Sun, S.; Zhao, G.; Dong, H. Tanshinone IIA elicits neuroprotective effect through activating the nuclear factor erythroid 2-related factor-dependent antioxidant response. Rejuvenation Res. 2017, 20, 286–297. [CrossRef] [PubMed]
98. Kuo, P.; Yu, I.; Scofield, B.A.; Brown, D.A.; Curfman, E.T.; Paraiso, H.C.; Chang, F.L.; Yen, J.H. 3H-1,2-Dithiole-3-thione as a novel therapeutic agent for the treatment of ischemic stroke through Nrf2 defense pathway. Brain Behav. Immun. 2017, 62, 180–192. [CrossRef] [PubMed]
99. Yang, J.; Su, J.; Wan, F.; Yang, N.; Jiang, H.; Fang, M.; Xiao, H.; Wang, J.; Tang, J.R. Tissue kallikrein protects against ischemic stroke by suppressing TLR4/NF-κB and activating Nrf2 signaling pathway in rats. Exp. Ther. Med. 2017, 14, 1163–1170. [CrossRef] [PubMed]
100. Scarmeas, N.; Stern, Y.; Mayeux, R.; Manly, J.; Schupf, N.; Luchsinger, J.A. Mediterranean diet and mild cognitive impairment. Arch. Neurol. 2009, 66, 216–225. [CrossRef] [PubMed]
101. Scarmeas, N.; Stern, Y.; Tang, M.; Mayeux, R.; Luchsinger, J.A. Mediterranean diet and risk for Alzheimer’s disease. Ann. Neurol. 2006, 59, 912–921. [CrossRef] [PubMed]
102. Valls-Pedret, C.; Sala-Vila, A.; Serra-Mir, M.; Corella, D.; De la Torre, R.; Martínez-González, M.Á.; Martínez-Lapiscina, E.H.; Fitó, M.; Pérez-Heras, A.; Salas-Salvadó, J., et al. Mediterranean diet and age-related cognitive decline. JAMA Intern. Med. 2015, 175, 1094. [CrossRef] [PubMed]
103. Rodriguez-Morato, J.; Boronat, A.; Dierssen, M.; De la Torre, R. Neuroprotective properties of wine: Implications for the prevention of cognitive impairment. In Role of the Mediterannean Diet in the Brain and Neurodegenerative Diseases, 1st ed.; Farooqui, T., Farooqui, A., Eds.; Elsevier: San Diego, CA, USA, 2018; in press; ISBN 9780128119594.
104. Innamorato, N.G.; Rojo, A.I.; García-Yagüe, Á.J.; Yamamoto, M.; De Ceballos, M.L.; Cuadrado, A. The transcription factor Nrf2 is a therapeutic target against brain inflammation. J. Immunol. 2008, 181, 680–689. [CrossRef] [PubMed]
105. Xicota, L.; Rodriguez-Morato, J.; Dierssen, M.; De La Torre, R. Potential Role of (-)-epigallocatechin-3-gallate (EGCG) in the secondary prevention of Alzheimer disease. Curr. Drug Targets 2017, 18, 174–195. [CrossRef] [PubMed]
106. Peng, S.; Zhang, B.; Yao, J.; Duan, D.; Fang, J. Dual protection of hydroxytyrosol, an olive oil polyphenol, against oxidative damage in PC12 cells. Food Funct. 2015, 6, 2091–2100. [CrossRef] [PubMed]
107. Bigagli, E.; Cinci, L.; Paccosi, S.; Parenti, A.; Ambrosio, M.D.; Luceri, C. Nutritionally relevant concentrations of resveratrol and hydroxytyrosol mitigate oxidative burst of human granulocytes and monocytes and the production of pro-inflammatory mediators in LPS-stimulated RAW264.7 macrophages. Int. Immunopharmacol. 2017, 43, 147–155. [CrossRef] [PubMed]
108. Visioli, F.; Bellomo, G.; Galli, C. Free radical-scavenging properties of olive oil polyphenols. Biochem. Biophys. Res. Commun. 1998, 247, 60–64. [CrossRef] [PubMed]
109. Goldstein, D.S.; Jinsmaa, Y.; Sullivan, P.; Holmes, C.; Kopin, I.J.; Sharabi, Y. 3,4-Dihydroxyphenylethanol (hydroxytyrosol) mitigates the increase in spontaneous oxidation of dopamine during monoamine oxidase inhibition in PC12 cells. Neurochem. Res. 2016, 41, 2173–2178. [CrossRef] [PubMed]
110. Mohan, V.; Das, S.; Rao, S.B.S. Hydroxytyrosol, a dietary phenolic compound forestalls the toxic effects of methylmercury-induced toxicity in IMR-32 human neuroblastoma cells. Environ. Toxicol. 2015, 31, 1264–1275. [CrossRef] [PubMed]
111. Tasset, I.; Pontes, A.J.; Hinojosa, A.J.; De la Torre, R.; Túnez, I. Olive oil reduces oxidative damage in a 3-nitropropionic acid-induced Huntington’s disease-like rat model. Nutr. Neurosci. 2011, 14, 106–111. [CrossRef] [PubMed]
112. Zheng, A.; Li, H.; Cao, K.; Xu, J.; Zou, X.; Li, Y.; Chen, C.; Liu, J.K.; Feng, Z.H. Maternal hydroxytyrosol administration improves neurogenesis and cognitive function in prenatally stressed offspring. J. Nutr. Biochem. 2015, 26, 190–199. [CrossRef] [PubMed]
113. Crespo, M.C.; Tomé-Carneiro, J.; Burgos-Ramos, E.; Loria Kohen, V.; Espinosa, M.I.; Herranz, J.; Visioli, F. One-week administration of hydroxytyrosol to humans does not activate Phase II enzymes. Pharmacol. Res. 2015, 95–96, 132–137. [CrossRef] [PubMed]
114. Bu, Y.; Rho, S.; Kim, J.; Yeon, M.; Hee, D.; Yeou, S.; Choi, H.; Kim, H. Neuroprotective effect of tyrosol on transient focal cerebral ischemia in rats. Neurosci. Lett. 2007, 414, 218–221. [CrossRef] [PubMed]
115. Vauzour, D.; Corona, G.; Spencer, J.P.E. Caffeic acid, tyrosol and p-coumaric acid are potent inhibitors of 5-S-cysteinyl-dopamine induced neurotoxicity. Arch. Biochem. Biophys. 2010, 501, 106–111. [CrossRef] [PubMed]
116. Dewapriya, P.; Himaya, S.W.A.; Li, Y.; Kim, S. Tyrosol exerts a protective effect against dopaminergic neuronal cell death in in vitro model of Parkinson’s disease. Food Chem. 2013, 141, 1147–1157. [CrossRef] [PubMed]
117. Wang, W.; Xia, Y.; Yang, B.; Su, X.; Chen, J.; Li, W.; Jiang, T. Protective effects of tyrosol against LPS-Induced acute lung injury via inhibiting NF-κB and AP-1 activation and activating the HO-1/Nrf2 pathways. Biol. Pharm. Bull. 2017, 40, 583–593. [CrossRef] [PubMed]
118. Nabavi, S.F.; Barber, A.J.; Spagnuolo, C.; Russo, G.L.; Daglia, M.; Nabavi, S.M.; Sobarzo-Sanchez, E. Nrf2 as molecular target for polyphenols: A novel therapeutic strategy in diabetic retinopathy. Crit. Rev. Clin. Lab. Sci. 2016, 53, 293–312. [CrossRef] [PubMed]
119. Omar, S.H. Cardioprotective and neuroprotective roles of oleuropein in olive. Saudi Pharm. J. 2010, 18, 111–121. [CrossRef] [PubMed]
120. Grossi, C.; Rigacci, S.; Ambrosini, S.; Dami, T.E.; Luccarini, I.; Traini, C.; Failli, P.; Berti, A.; Casamenti, F.; Stefani, M. The polyphenol oleuropein aglycone protects TgCRND8 mice against Aβ plaque pathology. PLoS ONE 2013, 8, e71702. [CrossRef] [PubMed]
121. Luccarini, I.; Grossi, C.; Rigacci, S.; Coppi, E.; Pugliese, A.M.; Pantano, D.; Marca, G.L.; Dami, T.E.; Berti, A.; Stefani, M., et al. Oleuropein aglycone protects against pyroglutamylated-3 amyloid-β toxicity: Biochemical, epigenetic and functional correlates. Neurobiol. Aging 2015, 36, 648–663. [CrossRef] [PubMed]
122. Pantano, D.; Luccarini, I.; Nardiello, P.; Servili, M.; Stefani, M.; Casamenti, F. Oleuropein aglycone and polyphenols from olive mill waste water ameliorate cognitive deficits and neuropathology. Br. J. Clin. Pharmacol. 2017, 83, 54–62. [CrossRef] [PubMed]
123. Diomede, L.; Rigacci, S.; Romeo, M.; Stefani, M.; Salmona, M. Oleuropein aglycone protects transgenic C. elegans strains expressing Ab42 by reducing plaque load and motor deficit. PLoS ONE 2013, 8. [CrossRef] [PubMed]
124. Pasban-Aliabadi, H.; Esmaeili-Mahani, S.; Sheibani, V.; Abbasnejad, M.; Mehdizadeh, A.; Yaghoobi, M.M. Inhibition of 6-hydroxydopamine-induced PC12 cell apoptosis by olive (Olea europaea L.) leaf extract is performed by its main component oleuropein. Rejuvenation Res. 2013, 16, 134–142. [CrossRef] [PubMed]
125. Achour, I.; Arel-Dubeau, A.-M.; Renaud, J.; Legrand, M.; Attard, E.; Germain, M.; Martinoli, M.-G. Oleuropein prevents neuronal death, mitigates mitochondrial superoxide production and modulates autophagy in a dopaminergic cellular model. Int. J. Mol. Sci. 2016, 17, 1293. [CrossRef] [PubMed]
126. Kim, M.H.; Min, J.; Lee, J.Y.; Chae, U.; Yang, E.; Song, K.; Lee, H.; Lee, H.; Lee, S.; Lee, D. Oleuropein isolated from Fraxinus rhynchophylla inhibits glutamate-induced neuronal cell death by attenuating mitochondrial dysfunction Oleuropein isolated from Fraxinus rhynchophylla inhibits glutamate-induced neuronal cell death by attenuating mitochond. Nutr. Neurosci. 2017. [CrossRef] [PubMed]
127. Parzonko, A.; Czerwinska, M.E.; Kiss, A.K.; Naruszewicz, M. Oleuropein and oleacein may restore biological functions of endothelial progenitor cells impaired by angiotensin II via activation of Nrf2/heme oxygenase-1 pathway. Phytomedicine 2013, 20, 1088–1094. [CrossRef] [PubMed]
128. Sun, W.; Wang, X.; Hou, C.; Yang, L.; Li, H.; Guo, J.; Huo, C.J.; Wang, M.L.; Miao, Y.W.; Liu, J.K., et al. Oleuropein improves mitochondrial function to attenuate oxidative stress by activating the Nrf2 pathway in the hypothalamic paraventricular nucleus of spontaneously hypertensive rats. Neuropharmacology 2017, 113, 556–566. [CrossRef] [PubMed]
129. Shen, C.; Cheng, W.; Yu, P.; Wang, L.; Zhou, L.; Zeng, L.; Yang, Q. Resveratrol pretreatment attenuates injury and promotes proliferation of neural stem cells following oxygen-glucose deprivation/reoxygenation by upregulating the expression of Nrf2, HO-1 and NQO1 in vitro. Mol. Med. Rep. 2016, 14, 3646–3654. [CrossRef] [PubMed]
130. Son, Y.; Byun, S.J.; Pae, H.-O. Involvement of heme oxygenase-1 expression in neuroprotection by piceatannol, a natural analog and a metabolite of resveratrol, against glutamate-mediated oxidative injury in HT22 neuronal cells. Amino Acids 2013, 45, 393–401. [CrossRef] [PubMed]
131. Narayanan, S.V.; Dave, K.R.; Saul, I.; Perez-Pinzon, M.A. Resveratrol preconditioning protects against cerebral ischemic injury via nuclear erythroid 2-related factor2. Stroke 2015, 46, 1626–1632. [CrossRef] [PubMed]
132. Ren, J.; Fan, C.; Chen, N.; Huang, J.; Yang, Q. Resveratrol pretreatment attenuates cerebral ischemic injury by upregulating expression of transcription factor Nrf2 and HO-1 in rats. Neurochem. Res. 2011, 36, 2352–2362. [CrossRef] [PubMed]
133. Gaballah, H.H.; Zakaria, S.S.; Elbatsh, M.M.; Tahoon, N.M. Modulatory effects of resveratrol on endoplasmic reticulum stress-associated apoptosis and oxido-inflammatory markers in a rat model of rotenone-induced Parkinson’s disease. Chem. Biol. Interact. 2016, 251, 10–16. [CrossRef] [PubMed]
134. Kumar, A.; Singh, C.K.; Lavoie, H.A.; Dipette, D.J.; Singh, U.S. Resveratrol restores Nrf2 level and prevents ethanol-induced toxic effects in the cerebellum of a rodent model of fetal alcohol spectrum disorders. Mol. Pharmacol. 2011, 80, 446–457. [CrossRef] [PubMed]
135. Lyros, E.; Bakogiannis, C.; Liu, Y.; Fassbender, K. Molecular links between endothelial dysfunction and neurodegeneration in Alzheimer’s disease. Curr. Alzheimer Res. 2014, 11, 18–26. [CrossRef] [PubMed]
136. Toda, N.; Ayajiki, K.; Okamura, T. Obesity-induced cerebral hypoperfusion derived from endothelial dysfunction: One of the risk factors for Alzheimer’s disease. Curr. Alzheimer Res. 2014, 11, 733–744. [CrossRef] [PubMed]
137. Ungvari, Z.; Bagi, Z.; Feher, A.; Recchia, F.A.; Sonntag, W.E.; Pearson, K.; Cabo, R.D.; Csiszar, A. Resveratrol confers endothelial protection via activation of the antioxidant transcription factor Nrf2. Am. J. Physiol. Heart Circ. Physiol. 2010, 299, H18–H24. [CrossRef] [PubMed]
138. Moussa, C.; Hebron, M.; Huang, X.; Ahn, J.; Rissman, R.A.; Aisen, P.S.; Turner, R.S. Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease. J. Neuroinflamm. 2017, 14, 1. [CrossRef] [PubMed]
139. Ghanim, H.; Sia, C.L.; Korzeniewski, K.; Lohano, T.; Abuaysheh, S.; Marumganti, A.; Chaudhuri, A.; Dandona, P. A resveratrol and polyphenol preparation suppresses oxidative and inflammatory stress response to a high-fat, high-carbohydrate meal. J. Clin. Endocrinol. Metab. 2011, 96, 1409–1414. [CrossRef] [PubMed]
140. Saldanha, J.F.; Leal, V.O.; Rizzetto, F.; Grimmer, G.H.; Ribeiro-Alves, M.; Daleprane, J.B.; Carraro-Eduardo, J.C.; Mafra, D. Effects of resveratrol supplementation in Nrf2 and NF-κB expressions in nondialyzed chronic kidney disease patients: A randomized, double-blind, placebo-controlled, crossover clinical trial. J. Ren. Nutr. 2016, 26, 401–406. [CrossRef] [PubMed]
141. Bahia, P.K.; Rattray, M.; Williams, R.J. The dietary flavonoid (-)epicatechin stimulates phosphatidylinositol 3-kinase dependent antioxidant response element activity and upregulates glutathione in cortical astrocytes. J. Neurochem. 2008, 106, 2194–2204. [CrossRef] [PubMed]
142. Shah, Z.A.; Li, R.-C.; Ahmad, A.S.; Kensler, T.W.; Yamamoto, M.; Biswal, S.; Dore, S. The flavanol (-)-epicatechin prevents stroke damage through the Nrf2/HO1 pathway. J. Cereb. Blood Flow Metab. 2010, 30, 1951–1961. [CrossRef] [PubMed]
143. Wu, S.; Yue, Y.; Li, J.; Li, Z.; Li, X.; Niu, Y.; Xiang, J.; Ding, H. Procyanidin B2 attenuates neurological deficits and blood-brain barrier disruption in a rat model of cerebral ischemia. Mol. Nutr. Food Res. 2015, 59, 1930–1941. [CrossRef] [PubMed]
144. Wu, B.-K.; Yuan, R.-Y.; Chang, Y.-P.; Lien, H.-W.; Chen, T.-S.; Chien, H.-C.; Tong, T.S.; Tsai, H.P.; Fang, C.L.; Liao, Y.F., et al. Epicatechin isolated from Tripterygium wilfordii extract reduces tau-GFP-induced neurotoxicity in zebrafish embryo through the activation of Nrf2. Biochem. Biophys. Res. Commun. 2016, 477, 283–289. [CrossRef] [PubMed]
145. Tanigawa, S.; Fujii, M.; Hou, D.-X. Action of Nrf2 and Keap1 in ARE-mediated NQO1 expression by quercetin. Free Radic. Biol. Med. 2007, 42, 1690–1703. [CrossRef] [PubMed]
146. Arredondo, F.; Echeverry, C.; Abin-Carriquiry, J.A.; Blasina, F.; Antúnez, K.; Jones, D.P.; Go, Y.-M.; Liang, Y.-F.; Dajas, F. After cellular internalization, quercetin causes Nrf2 nuclear translocation, increases glutathione levels, and prevents neuronal death against an oxidative insult. Free Radic. Biol. Med. 2010, 49, 738–747. [CrossRef] [PubMed]
147. Li, X.; Wang, H.; Gao, Y.; Li, L.; Tang, C.; Wen, G.; Zhou, Y.; Zhou, M.L.; Mao, L.; Fan, Y.W. Protective effects of quercetin on mitochondrial biogenesis in experimental traumatic brain injury via the Nrf2 signaling pathway. PLoS ONE 2016. [CrossRef] [PubMed]
148. Dong, F.; Wang, S.; Wang, Y.; Yang, X.; Jiang, J.; Wu, D.; Qu, X.; Fan, H.; Yao, R. Quercetin ameliorates learning and memory via the Nrf2-ARE signaling pathway in d-galactose-induced neurotoxicity in mice. Biochem. Biophys. Res. Commun. 2017, 491, 636–641. [CrossRef] [PubMed]
149. Covas, M.I.; Konstantinidou, V.; Mysytaki, E.; Fitó, M.; Weinbrenner, T.; De La Torre, R.; Farre-Albadalejo, M.; Lamuela-Raventos, R. Postprandial effects of wine consumption on lipids and oxidative stress biomarkers. Drugs Exp. Clin. Res. 2003, 29, 217–223. [PubMed]
150. Fernández-Pachón, M.S.; Berná, G.; Otaolaurruchi, E.; Troncoso, A.M.; Martín, F.; García-Parrilla, M.C. Changes in antioxidant endogenous enzymes (activity and gene expression levels) after repeated red wine intake. J. Agric. Food Chem. 2009, 57, 6578–6583. [CrossRef] [PubMed]
151. Noguer, M.A.; Cerezo, A.B.; Donoso Navarro, E.; Garcia-Parrilla, M.C. Intake of alcohol-free red wine modulates antioxidant enzyme activities in a human intervention study. Pharmacol. Res. 2012, 65, 609–614. [CrossRef] [PubMed]
152. Johnson, W.M.; Wilson-Delfosse, A.L.; Mieyal, J.J. Dysregulation of glutathione homeostasis in neurodegenerative diseases. Nutrients 2012, 4, 1399–1440. [CrossRef] [PubMed]
153. Wu, L.; Sun, D. Adherence to Mediterranean diet and risk of developing cognitive disorders: An updated systematic review and meta-analysis of prospective cohort studies. Sci. Rep. 2017, 7, 41317–41326. [CrossRef] [PubMed]
154. Martínez-Lapiscina, E.H.; Clavero, P.; Toledo, E.; Estruch, R.; Salas-Salvadó, J.; San Julián, B.; Sanchez-Tainta, A.; Ros, E.; Valls-Pedret, C.; Martinez-Gonzalez, M.A. Mediterranean diet improves cognition: The PREDIMED-NAVARRA randomised trial. J. Neurol. Neurosurg. Psychiatry 2013, 84, 1318–1325. [CrossRef] [PubMed]
155. Martinez-Lapiscina, E.H.; Clavero, P.; Toledo, E.; San Julian, B.; Sanchez-Tainta, A.; Corella, D.; Lamuela-Raventos, R.M.; Martinez, J.A.; Martinez-Gonzalez, M.A. Virgin olive oil supplementation and long-term cognition: The Predimed-Navarra randomized, trial. J. Nutr. Health. Aging 2013, 17, 544–552. [CrossRef] [PubMed]
156. Barba, F.J.; Zhu, Z.; Koubaa, M.; Sant’Ana, A.S.; Orlien, V. Green alternative methods for the extraction of antioxidant bioactive compounds from winery wastes and by-products: A review. Trends Food Sci. Technol. 2016, 49, 96–109. [CrossRef]
157. Roselló-Soto, E.; Koubaa, M.; Moubarik, A.; Lopes, R.P.; Saraiva, J.A.; Boussetta, N.; Grimi, N.; Barba, F.J. Emerging opportunities for the effective valorization of wastes and by-products generated during olive oil production process: Non-conventional methods for the recovery of high-added value compounds. Trends Food Sci. Technol. 2015, 45, 296–310. [CrossRef]
158. Ramsey, C.P.; Glass, C.A.; Montgomery, M.B.; Lindl, K.A.; Ritson, G.P.; Chia, L.A.; Hamilton, R.L.; Chu, C.T. Expression of Nrf2 in neurodegenerative diseases. J. Neuropathol. Exp. Neurol. 2007, 66, 75–85. [CrossRef] [PubMed]